Showing results (151-160 of 280) with videos related to

Sort By:
Pageof 28
Cancer Chemotherapy and Pharmacology|February 25, 2025
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumorsSusan C Scott, Anna Farago, W Victoria Lai, et al.
Blood Advances|May 21, 2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United StatesAmer M Zeidan, Rong Wang, Xiaoyi Wang, et al.
Cancer Medicine|September 13, 2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemiaNikolai A Podoltsev, Rong Wang, Rory M Shallis, et al.
Leukemia Research|September 28, 2014
Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenograftsPragya Srivastava, Benjamin E Paluch, Junko Matsuzaki, et al.
Stem Cell Research|February 5, 2026
Generation of an induced pluripotent stem cell line CGOi001-A from a patient with hereditary thrombocytopenia and a germline ANKRD26 mutationAubrianna S Ramsland, Karolina Dudek, Kelsey E McNeely, et al.
British Journal of Haematology|February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-CPierre Fenaux, Norbert Gattermann, John F Seymour, et al.
British Journal of Haematology|October 7, 2009
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology GroupMark R Litzow, Megan Othus, Larry D Cripe, et al.
Blood|August 5, 2009
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylationMaria E Figueroa, Lucy Skrabanek, Yushan Li, et al.
Blood Advances|August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemiaBrian Ball, Rami S Komrokji, Lionel Adès, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemiaSteven D Gore, Li-Jun Weng, William D Figg, et al.
Pageof 28